Practical articles organized by catalog use, documentation review, custom planning, and research procurement.
Choose a category to narrow the published guidance.
13 articles
This article answers the 10 most common questions about TB-500 and thymosin beta-4 in a Q&A format, covering differences, human trials, vendor confusion, missing mechanisms, and the Rahaman 2024 finding.
Read guidance →
The Paradigm case is not just one vendor getting caught. It is changing the rules of the peptide market, the way buyers evaluate products, and the marketing tactics vendors use to borrow the case. This article explains three real impacts.
Read guidance →
CJC-1295 and Ipamorelin do raise growth hormone and IGF-1 as the pharmacology says, but the combination has never been tested in humans, the short-acting form has never been tested in humans, and neither compound has a human study measuring muscle, fat, recovery, or sleep. This article offers an honest assessment.
Read guidance →
A 50 mg GHK-Cu vial contains about 8 mg of elemental copper. Injected copper bypasses gut regulation, and no human study has measured copper levels after weeks of subcutaneous copper peptide injections. This article explains the unknown risk.
Read guidance →
As of 31 May 2026, the FDA had recorded 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Cagrilintide has no legal compounding pathway and comes from the same unregulated supply chain. This article lays out the known risks: purity, endotoxins, label accuracy and premix ratio consistency.
Read guidance →
Retatrutide has not yet run discontinuation or maintenance trials. Semaglutide and tirzepatide both show significant rebound after stopping. This article explains the gap and why rebound is a reasonable expectation, but not a research finding.
Read guidance →
Lyophilized and pre-mixed liquid peptides differ fundamentally in stability, storage, and reconstitution. This article explains the advantages of lyophilization, the role of bacteriostatic water, and how reconstitution affects peptide activity.
Read guidance →
One of the most consistent findings in animal research is that BPC-157 helps generate new blood vessels. This article explains its relationship with VEGF, angiogenesis, and vascular repair, and why this mechanism is thought to be linked to tissue healing.
Read guidance →
The legal status of peptide drugs varies from country to country. This article explains the regulatory frameworks of the U.S. FDA, the European EMA, Australia's TGA, and the World Anti-Doping Agency (WADA), and why the same peptide may be legal or restricted in different regions.
Read guidance →
A practical checklist for identifying a catalog record and giving the review team enough information to answer accurately.
Read guidance →
Understand the difference between a catalog statement, a mapped historical file, and documentation for the material currently being quoted.
Read guidance →
The sequence, modification, purity, quantity, analytical, destination, and timing details that make a custom request reviewable.
Read guidance →
A controlled way to compare identity, specification, evidence, destination requirements, and lead time before a purchase decision.
Read guidance →